MolecularMatch, a clinical informatics company providing Precision Medicine software solutions for oncology, announced the release of MMPower v4, the latest update to its Clinical Decision Support Platform. This new release adds expanded therapeutic guidance and a new Software Developer's Kit ( SDK) to broaden language support and speed up time-to-market for software developers writing custom applications integrating with the MolecularMatch platform.
Key new features for MolecularMatch's expanded therapeutic guidance include:
- Expanded pharmacology details including mechanism of action, toxicity, contraindication, and drug metabolism
- Regional approval status now includes EMA and HCA in addition to FDA
- Dosage options
- Pricing specifics